ATE319737T1 - Peptidderivate des apolipoproteins-a1/aii - Google Patents
Peptidderivate des apolipoproteins-a1/aiiInfo
- Publication number
- ATE319737T1 ATE319737T1 AT01930664T AT01930664T ATE319737T1 AT E319737 T1 ATE319737 T1 AT E319737T1 AT 01930664 T AT01930664 T AT 01930664T AT 01930664 T AT01930664 T AT 01930664T AT E319737 T1 ATE319737 T1 AT E319737T1
- Authority
- AT
- Austria
- Prior art keywords
- apo
- amphipathic helix
- domain
- helix peptide
- peptide
- Prior art date
Links
- 102000005666 Apolipoprotein A-I Human genes 0.000 title abstract 14
- 108010059886 Apolipoprotein A-I Proteins 0.000 title abstract 14
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 102000009081 Apolipoprotein A-II Human genes 0.000 title 1
- 108010087614 Apolipoprotein A-II Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000002823 phage display Methods 0.000 abstract 2
- 238000012216 screening Methods 0.000 abstract 2
- 229920002307 Dextran Polymers 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003278 mimic effect Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19892000P | 2000-04-21 | 2000-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE319737T1 true ATE319737T1 (de) | 2006-03-15 |
Family
ID=22735445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01930664T ATE319737T1 (de) | 2000-04-21 | 2001-04-23 | Peptidderivate des apolipoproteins-a1/aii |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6743778B2 (https=) |
| EP (1) | EP1290013B1 (https=) |
| JP (1) | JP2003530870A (https=) |
| AT (1) | ATE319737T1 (https=) |
| AU (2) | AU2001257173B2 (https=) |
| CA (1) | CA2407083A1 (https=) |
| DE (1) | DE60117781T2 (https=) |
| DK (1) | DK1290013T3 (https=) |
| ES (1) | ES2260219T3 (https=) |
| MX (1) | MXPA02010324A (https=) |
| PT (1) | PT1290013E (https=) |
| WO (1) | WO2001081376A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2407086A1 (en) * | 2000-04-21 | 2001-11-01 | Amgen, Inc. | Integrin/adhesion antagonists |
| US8116889B2 (en) * | 2002-06-27 | 2012-02-14 | Openpeak Inc. | Method, system, and computer program product for managing controlled residential or non-residential environments |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7329725B1 (en) * | 2003-10-29 | 2008-02-12 | Nastech Pharmaceutical Company Inc. | Phage displayed Trp cage ligands |
| US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
| ATE555133T1 (de) | 2003-11-13 | 2012-05-15 | Hanmi Holdings Co Ltd | Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung |
| WO2006063132A2 (en) * | 2004-12-06 | 2006-06-15 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
| US7704953B2 (en) * | 2006-02-17 | 2010-04-27 | Mdrna, Inc. | Phage displayed cell binding peptides |
| WO2007103775A2 (en) * | 2006-03-03 | 2007-09-13 | Washington University In St. Louis | Biomaterials having nanoscale layers and coatings |
| CA2653840A1 (en) * | 2006-06-01 | 2007-12-06 | Institut De Cardiologie De Montreal | Use of a peptide/phospholipid complex acting as a reverse lipid transport agonist for treatment of valvular stenosis |
| AU2014268255B2 (en) * | 2009-02-16 | 2016-04-21 | Cerenis Therapeutics Holding Sa | Apolipoprotein a-i mimics |
| LT2939683T (lt) | 2009-02-16 | 2017-03-27 | Cerenis Therapeutics Holding Sa | Apolipoproteino a-i mimetikai |
| WO2015173633A2 (en) | 2014-05-02 | 2015-11-19 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
| WO2016154544A1 (en) | 2015-03-25 | 2016-09-29 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| EP3490579B1 (en) | 2016-07-27 | 2025-09-10 | Hartis-Pharma SA | Therapeutic combinations to treat red blood cell disorders |
| KR20230004605A (ko) | 2020-04-16 | 2023-01-06 | 아비오닉스 파마 에스에이 | 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법 |
| MX2023003877A (es) | 2020-10-01 | 2023-04-18 | Abionyx Pharma Sa | Composiciones que comprenden complejos basados en proteina de union a lipidos para usarse en el tratamiento de enfermedades oculares. |
| KR20240018430A (ko) | 2021-04-15 | 2024-02-13 | 아비오닉스 파마 에스에이 | 기관 보존 용액에서의 지질 결합 단백질-기반 복합체의 사용 |
| AU2023250345A1 (en) | 2022-04-06 | 2024-11-14 | Abionyx Pharma Sa | Methods for treating eye diseases using lipid binding protein-based complexes |
| CA3247588A1 (en) | 2022-04-06 | 2023-10-12 | Abionyx Pharma Sa | METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID-BINDING PROTEIN COMPLEXES |
| WO2023237927A2 (en) | 2022-06-10 | 2023-12-14 | Abionyx Pharma Sa | Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes |
| JP2025519606A (ja) | 2022-06-10 | 2025-06-26 | アビオニクス ファーマ エスエー | 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法 |
| WO2024150064A1 (en) | 2023-01-13 | 2024-07-18 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
| WO2025093929A1 (en) | 2023-10-31 | 2025-05-08 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| EP0545913B1 (en) | 1986-08-18 | 1999-02-24 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| SE9103701D0 (sv) | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
| CA2118130A1 (en) | 1992-04-14 | 1993-10-28 | Jean M. J. Frechet | Dendritic based macromolecules and method of production |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
| JP4046354B2 (ja) * | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US6156727A (en) | 1996-09-05 | 2000-12-05 | Uab Research Foundation | Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis |
| EP0934526B1 (en) | 1996-10-08 | 2003-01-08 | U-BISys B.V. | Methods and means for selecting peptides and proteins having specific affinity for a target |
| US6046166A (en) * | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| GB9815505D0 (en) | 1998-07-16 | 1998-09-16 | Adprotech Plc | Polypeptide derivatives |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
-
2001
- 2001-04-23 AU AU2001257173A patent/AU2001257173B2/en not_active Ceased
- 2001-04-23 EP EP01930664A patent/EP1290013B1/en not_active Expired - Lifetime
- 2001-04-23 JP JP2001578463A patent/JP2003530870A/ja not_active Withdrawn
- 2001-04-23 PT PT01930664T patent/PT1290013E/pt unknown
- 2001-04-23 DK DK01930664T patent/DK1290013T3/da active
- 2001-04-23 AU AU5717301A patent/AU5717301A/xx active Pending
- 2001-04-23 US US09/840,669 patent/US6743778B2/en not_active Expired - Fee Related
- 2001-04-23 WO PCT/US2001/013068 patent/WO2001081376A2/en not_active Ceased
- 2001-04-23 CA CA002407083A patent/CA2407083A1/en not_active Abandoned
- 2001-04-23 ES ES01930664T patent/ES2260219T3/es not_active Expired - Lifetime
- 2001-04-23 AT AT01930664T patent/ATE319737T1/de not_active IP Right Cessation
- 2001-04-23 MX MXPA02010324A patent/MXPA02010324A/es unknown
- 2001-04-23 DE DE60117781T patent/DE60117781T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001081376A3 (en) | 2003-01-09 |
| ES2260219T3 (es) | 2006-11-01 |
| DE60117781T2 (de) | 2006-11-23 |
| EP1290013A2 (en) | 2003-03-12 |
| EP1290013B1 (en) | 2006-03-08 |
| PT1290013E (pt) | 2006-06-30 |
| DE60117781D1 (de) | 2006-05-04 |
| DK1290013T3 (da) | 2006-06-26 |
| JP2003530870A (ja) | 2003-10-21 |
| US6743778B2 (en) | 2004-06-01 |
| WO2001081376A2 (en) | 2001-11-01 |
| CA2407083A1 (en) | 2001-11-01 |
| MXPA02010324A (es) | 2003-04-25 |
| AU5717301A (en) | 2001-11-07 |
| US20030040470A1 (en) | 2003-02-27 |
| AU2001257173B2 (en) | 2005-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE319737T1 (de) | Peptidderivate des apolipoproteins-a1/aii | |
| WO2001083527A3 (en) | Glucagon antagonists | |
| Atoda et al. | The primary structure of coagulation factor IX/factor X-binding protein isolated from the venom of Trimeresurus flavoviridis. Homology with asialoglycoprotein receptors, proteoglycan core protein, tetranectin, and lymphocyte Fc epsilon receptor for immunoglobulin E | |
| AU764589B2 (en) | Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease | |
| EA200201121A1 (ru) | Модуляторы рецепторов паратироидного гормона и родственного паратироидному гормону белка | |
| ES2312369T3 (es) | Nuevos peptidos quimericos analgesicos. | |
| McGavin et al. | Fibronectin binding determinants of the Staphylococcus aureus fibronectin receptor | |
| YU95203A (sh) | Peptidi i njima srodni molekuli koji se vezuju za tall-1 | |
| DE60327786D1 (de) | Kdr-peptide und diese enthaltende impfstoffe | |
| WO2005051998A3 (en) | Antibodies binding to a c-terminal fragment of apolipoprotein e | |
| Himeshima et al. | Amino acid sequence of a lectin from the sea cucumber, Stichopus japonicus, and its structural relationship to the C-type animal lectin family | |
| Lycksell et al. | 1H NMR studies of mouse ribonucleotide reductase: the R2 protein carboxyl-terminal tail, essential for subunit interaction, is highly flexible but becomes rigid in the presence of protein R1 | |
| US6469138B1 (en) | Thrombospondin receptor binding peptides | |
| IL175319A0 (en) | Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof | |
| WO2001083526A3 (en) | Calcitonin-related molecules | |
| JP2004505640A5 (https=) | ||
| Shibata et al. | Improvement of biological activity and proteolytic stability of peptides by coupling with a cyclic peptide | |
| JPH05502046A (ja) | フィブロネクチン結合タンパク質 | |
| Bánóczi et al. | Synthesis of cell-penetrating conjugates of calpain activator peptides | |
| Thurieau et al. | Design and synthesis of new linear and cyclic bradykinin antagonists | |
| DE69732583D1 (de) | Verfahren zur Spaltung eines chimeren Proteins mittels eines 'processing'-Enzyms | |
| WO1996004926A1 (en) | TWO NON-CONTIGUOUS REGIONS CONTRIBUTE TO NIDOGEN BINDING TO A SINGLE EGF-LIKE MOTIF OF THE LAMININ η1 CHAIN | |
| ATE223927T1 (de) | Mu-opioidligande: agonisten und antagonisten | |
| WO2005041882A3 (en) | Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs | |
| JPH06504260A (ja) | 両親媒性ペプチド組成物及びその類似体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1290013 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |